Translational studies have suggested that KRASMUT patients might respond well to ICB due to a larger proportion of smokers and a higher immunologically active tumor environment as a consequence of constitutive activation of KRAS and downstream signaling pathways [30,31,32,33,34,39,45,46]. Here, KRAS is linked to neoplasm.